Valeant Psoriasis Drug's Suicide Risk Hard to Assess -FDA StaffValeant Psoriasis Drug's Suicide Risk Hard to Assess -FDA Staff

Valeant Pharmaceuticals International Inc's experimental drug to treat psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, a preliminary review by the U.S. Food and Drug Administration said on Friday. Reuters Health Information
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Pharmacist News Source Type: news